Alzheimer's Drug From Biogen, Eisai Slows Cognitive Decline, Side-effects In Focus

The drug, lecanemab, was associated with a dangerous type of brain swelling in nearly 13 per cent of patients in the trial that spanned 18 months and enrolled nearly 1,800 participants with early-stage Alzheimer's